This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pisters, K. M.W. Articles by Lee, J. S. Search for Related Content PubMed PubMed Citation Articles by Pisters, K. M.W. Articles by Lee, J. S. Social Bookmarking                            What's this?

Phase I Trial of Oral Green Tea Extract in Adult Patients With Solid Tumors

From the University of Texas, M. D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Katherine M.W. Pisters, MD, Department of Thoracic/Head & Neck Medical Oncology, Division of Medicine, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 80, Houston, TX 77030; email: kpisters{at}mdanderson.org

PURPOSE: This trial was designed to determine the maximum-tolerated dose, toxicity, and pharmacology of oral green tea extract (GTE) once daily or three times daily.

PATIENTS AND METHODS: Cohorts of three or more adult cancer patients were administered oral GTE with water after meals one or three times daily for 4 weeks, to a maximum of 6 months, depending on disease response and patient tolerance. Pharmacokinetic analyses were encouraged but optional.

RESULTS: Dose levels of 0.5 to 5.05 g/m² qd and 1.0 to 2.2 g/m² tid were explored. A total of 49 patients were studied. Patient characteristics: median age, 57 years (range, 27 to 77 years); 23 patients were women (47%); 98% had a Zubrod PS of 1%; 98% had PS of 1; and 21 had non–small-cell lung, 19 had head & neck cancer, three had mesothelioma, and six had other. Mild to moderate toxicities were seen at most dose levels and promptly reversed on discontinuation of GTE. Dose-limiting toxicities were caffeine related and included neurologic and gastrointestinal effects. The maximum-tolerated dose was 4.2 g/m² once daily or 1.0 g/m² three times daily. No major responses occurred; 10 patients with stable disease completed 6 months of GTE. Pharmacokinetic analyses found accumulation of caffeine levels that were dose dependent, whereas epigallocatechin gallate levels did not accumulate nor appear dose related.

CONCLUSION: A dose of 1.0 g/m² tid (equivalent to 7 to 8 Japanese cups [120 mL] of green tea three times daily) is recommended for future studies. The side effects of this preparation of GTE were caffeine related. Oral GTE at the doses studied can be taken safely for at least 6 months.

Waun Ki Hong, MD, is an advisor to Ito En, Ltd.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. P. Moiseeva and M. M. Manson Dietary Chemopreventive Phytochemicals: Too Little or Too Much? Cancer Prevention Research, July 1, 2009; 2(7): 611 - 616. [Abstract] [Full Text] [PDF]

				A.R.M. R. Amin, O. Kucuk, F. R. Khuri, and D. M. Shin Perspectives for Cancer Prevention With Natural Compounds J. Clin. Oncol., June 1, 2009; 27(16): 2712 - 2725. [Abstract] [Full Text] [PDF]

				H. R. Kim, R. Rajaiah, Q.-L. Wu, S. R. Satpute, M. T. Tan, J. E. Simon, B. M. Berman, and K. D. Moudgil Green Tea Protects Rats against Autoimmune Arthritis by Modulating Disease-Related Immune Events J. Nutr., November 1, 2008; 138(11): 2111 - 2116. [Abstract] [Full Text] [PDF]

				F. R. Khuri and D. M. Shin Head and Neck Cancer Chemoprevention Gets a Shot in the Arm J. Clin. Oncol., January 20, 2008; 26(3): 345 - 347. [Full Text] [PDF]

				T. Nakazato, M. Sagawa, K. Yamato, M. Xian, T. Yamamoto, M. Suematsu, Y. Ikeda, and M. Kizaki Myeloperoxidase Is a Key Regulator of Oxidative Stress Mediated Apoptosis in Myeloid Leukemic Cells Clin. Cancer Res., September 15, 2007; 13(18): 5436 - 5445. [Abstract] [Full Text] [PDF]

				J. R. Carlson, B. A. Bauer, A. Vincent, P. J. Limburg, and T. Wilson Reading the Tea Leaves: Anticarcinogenic Properties of (-)-Epigallocatechin-3-Gallate Mayo Clin. Proc., June 1, 2007; 82(6): 725 - 732. [Abstract] [Full Text] [PDF]

				J. Kim, X. Zhang, K. M. Rieger-Christ, I. C. Summerhayes, D. E. Wazer, K. E. Paulson, and A. S. Yee Suppression of Wnt Signaling by the Green Tea Compound (-)-Epigallocatechin 3-Gallate (EGCG) in Invasive Breast Cancer Cells: REQUIREMENT OF THE TRANSCRIPTIONAL REPRESSOR HBP1 J. Biol. Chem., April 21, 2006; 281(16): 10865 - 10875. [Abstract] [Full Text] [PDF]

				D. R. Yance Jr and S. M. Sagar Targeting Angiogenesis With Integrative Cancer Therapies Integr Cancer Ther, March 1, 2006; 5(1): 9 - 29. [Abstract] [PDF]

				A. J. Vickers, J. Kuo, and B. R. Cassileth Unconventional Anticancer Agents: A Systematic Review of Clinical Trials J. Clin. Oncol., January 1, 2006; 24(1): 136 - 140. [Abstract] [Full Text] [PDF]

				M. F. McCarty and K. I. Block Multifocal Angiostatic Therapy: An Update Integr Cancer Ther, December 1, 2005; 4(4): 301 - 314. [Abstract] [PDF]

				T. Nakazato, K. Ito, Y. Ikeda, and M. Kizaki Green Tea Component, Catechin, Induces Apoptosis of Human Malignant B Cells via Production of Reactive Oxygen Species Clin. Cancer Res., August 15, 2005; 11(16): 6040 - 6049. [Abstract] [Full Text] [PDF]

				O. Aktas, T. Prozorovski, A. Smorodchenko, N. E. Savaskan, R. Lauster, P.-M. Kloetzel, C. Infante-Duarte, S. Brocke, and F. Zipp Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-{kappa}B Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis J. Immunol., November 1, 2004; 173(9): 5794 - 5800. [Abstract] [Full Text] [PDF]

				R. A. Sharma, S. A. Euden, S. L. Platton, D. N. Cooke, A. Shafayat, H. R. Hewitt, T. H. Marczylo, B. Morgan, D. Hemingway, S. M. Plummer, et al. Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance Clin. Cancer Res., October 15, 2004; 10(20): 6847 - 6854. [Abstract] [Full Text] [PDF]

				H. Nakagawa, K. Hasumi, J.-T. Woo, K. Nagai, and M. Wachi Generation of hydrogen peroxide primarily contributes to the induction of Fe(II)-dependent apoptosis in Jurkat cells by (-)-epigallocatechin gallate Carcinogenesis, September 1, 2004; 25(9): 1567 - 1574. [Abstract] [Full Text] [PDF]

				G. Fassina, R. Vene, M. Morini, S. Minghelli, R. Benelli, D. M. Noonan, and A. Albini Mechanisms of Inhibition of Tumor Angiogenesis and Vascular Tumor Growth by Epigallocatechin-3-Gallate Clin. Cancer Res., July 15, 2004; 10(14): 4865 - 4873. [Abstract] [Full Text] [PDF]

				H-H. S. Chow, Y. Cai, I. A. Hakim, J. A. Crowell, F. Shahi, C. A. Brooks, R. T. Dorr, Y. Hara, and D. S. Alberts Pharmacokinetics and Safety of Green Tea Polyphenols after Multiple-Dose Administration of Epigallocatechin Gallate and Polyphenon E in Healthy Individuals Clin. Cancer Res., August 1, 2003; 9(9): 3312 - 3319. [Abstract] [Full Text] [PDF]

				D. O. McCarthy Rethinking Nutritional Support for Persons with Cancer Cachexia Biol Res Nurs, July 1, 2003; 5(1): 3 - 17. [Abstract] [PDF]

				M.-J. Lee, P. Maliakal, L. Chen, X. Meng, F. Y. Bondoc, S. Prabhu, G. Lambert, S. Mohr, and C. S. Yang Pharmacokinetics of Tea Catechins after Ingestion of Green Tea and (-)-Epigallocatechin-3-gallate by Humans: Formation of Different Metabolites and Individual Variability Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1025 - 1032. [Abstract] [Full Text] [PDF]

				S. M. Lippman and W. K. Hong Cancer Prevention Science and Practice Cancer Res., September 15, 2002; 62(18): 5119 - 5125. [Full Text] [PDF]

				M. R. Sartippour, Z.-M. Shao, D. Heber, P. Beatty, L. Zhang, C. Liu, L. Ellis, W. Liu, V. L. Go, and M. N. Brooks Green Tea Inhibits Vascular Endothelial Growth Factor (VEGF) Induction in Human Breast Cancer Cells J. Nutr., August 1, 2002; 132(8): 2307 - 2311. [Abstract] [Full Text] [PDF]